NEW YORK (GenomeWeb News) – Transgenomic today reported that its first-quarter revenues fell 21 percent year over year, and the firm swung to a loss from a profit a year earlier.

The Omaha, Neb.-based pharmacogenomics firm brought in revenues of $5 million for the three-month period ended March 31, compared to $6.3 million for the first quarter of 2008.

"Unfortunately, like many companies today, we are also experiencing an impact from the overall economic slowdown," Transgenomic President and CEO Craig Tuttle said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.